The Motley Fool·1d ago
Why Labcorp Holdings Stock Dropped TodayMedicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Labcorp is executing a disciplined operational turnaround, evidenced by gross margin expansion from 28.2% in 2024Q1 to 29.8% in 2026Q2 and operating margin growth from 10.1% to 12.1% over the same period. Revenue growth has accelerated to 5.8% in 2026Q2, drive...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 5.8% in 2026Q2, with gross margin expanding to 29.8% and operating margin to 12.1%, reflecting improved cost discipline and mix shift.
Labcorp's collaboration with AWS and Datavant has created an AI-driven platform that leverages longitudinal laboratory data and advanced analytics to accelerate drug discovery and streamline processes.
Labcorp provides end-to-end drug development and clinical laboratory services, positioning it as a leader in guiding patient care and life sciences innovation.
The company has a strong legacy in genomic testing, including early adoption of PCR technology, enhancing its credibility and capabilities in molecular biology and pathology.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $4.99+4.4% vs $4.78 | $3.7B+0.6% vs $3.7B |
Q2 2026 Apr 30, 2026 | $4.25+3.4% vs $4.11 | $3.5B+0.8% vs $3.5B |
Q1 2026 Feb 17, 2026 | $4.07+3.0% vs $3.95 | $3.5B-1.2% vs $3.6B |
Q4 2025 Oct 28, 2025 | $4.18+1.2% vs $4.13 | $3.6B+0.2% vs $3.6B |
Medicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.
Benchmark LH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Labcorp Holdings Inc. (LH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $311.54 | $25.55B | 29.78 | 7.25% | 6.28% | 10.5% | 0.92% | |
| $234.85 | $25.92B | 26.84 | 11.78% | 9.19% | 14.09% | — | |
| $53.01 | $2.76B | 135.92 | — | 33.7% | 22.86% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $379.57 | $10.22B | 13.62 | 0.65% | 8.59% | 3.15% | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — |
Labcorp Holdings Inc. (LH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Labcorp Holdings Inc. (LH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 10, 2026·SEC
Jun 30, 2026·SEC
Get notified when LH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Labcorp Holdings Inc. (LH) stock FAQ — growth, dividends, profitability & financials explained
Labcorp Holdings Inc. (LH) reported $14.35B in revenue for fiscal year 2025. This represents a 792% increase from $1.61B in 1996.
Labcorp Holdings Inc. (LH) grew revenue by 7.2% over the past year. This is steady growth.
Yes, Labcorp Holdings Inc. (LH) is profitable, generating $1.00B in net income for fiscal year 2025 (6.3% net margin).
Yes, Labcorp Holdings Inc. (LH) pays a dividend with a yield of 0.92%. This makes it attractive for income-focused investors.
Labcorp Holdings Inc. (LH) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
Labcorp Holdings Inc. (LH) generated $1.16B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
